NRL of Measles, Mumps, Rubella
National Centre of Infectious and Parasitic Diseases
14 A General Stoletov blvd.
Head of Laboratory:
Assistant Professor Stefka Krumova, PhD
- Adelina Pavlova, biologist
- Krasimira Kasabova, medical laboratory assistant
- Emilia Stefanova, senior medical laboratory assistant
- Liliana Stoichkova, laboratory worker
History of laboratory
In 1974 the laboratory was created following the consolidation of existing laboratories "Measles" and "Mumps" and in 1978 the laboratory started to includes the problem "rubella".
By 2000 laboratory "Measles, mumps, rubella" is developing in several areas: scientific, viral diagnostic, production and training. Also seroepidemiological studies on the immune status of the population and control the effectiveness of the measles, mumps and rubella vaccines in Bulgaria and improving the quality of Bulgarian vaccine preparations (measles and mumps) and associated (measles / mumps) vaccines and diagnostic agents which are used for serological tests.
After 2000 the laboratory is primarily engaged in diagnostic (development of new serological and virological methods), developing scientific problems, education and training aimed at: postgraduate education of specialists from the healthcare network and student training and seroepidemiological studies on vaccine-preventable diseases - measles, mumps, and rubella.
By order of the Ministry of 04/06/2001, the lab receives reference functions for the country and was renamed the NRL "Measles, mumps, rubella."
Over the years, the laboratory has been headed by renowned experts in the field of virology, including Assoc. Prof. A. Mihailov to 2008 and Assoc. Prof. Dr. Z. Mihneva to 2014.
The activities of the NRL "Measles, mumps, rubella" include detection the role of measles, mumps, rubella and human parvovirus B19 in infectious pathology of the country with different diagnostic methods:
• Decryption etiology outbreaks of these infections;
• Differential diagnosis approach of laboratory testing of complicated clinical cases (including neurological complications, complications due to maternal-fetal infection, etc.);
• Monitoring the effect of specific control of these infections, testing of specific serological profile on group of risk: women of childbearing age, medical staff, immunocompromised persons, etc;
• Testing of immune status for rubella and parvovirus B19 of women of childbearing age and pregnant women which are in contact with fever-rash infections and women included in the "in vitro" fertilization program, etc .;
• Issuance of a medical certificate to persons for work and education abroad regarding immune status against infections measles, mumps and rubella;
• Study on the prevalence of human parvovirus B19 in the country and its participation in different clinical manifestations;
• Conducting active serological and molecular-epidemiological surveillance of fever-rash cases as part of the European laboratory network for measles and rubella (WHO / EURO Measles / Rubella Laboratory Network), and for the purposes of national vaccine programs in the period elimination of these infections; NRL must investigate, rejected or confirmed every possible case of measles and rubella in the country;
• NRL evaluated twice a year the quality of diagnostic work of the virological laboratories in the country about detection of specific antibodies against measles, mumps and rubella.
The diagnostic activity of NRL is related to the detection of basic markers of measles, mumps and rubella and is accredited by Standards BG EN ISO / IEC 17025.
NRL "Measles, mumps, rubella" is part of the Global Laboratory Network WHO measles and rubella (The WHO Global Measles/Rubella Laboratory Network) and participates annually in several international programs for external control and quality assessment of diagnostic work (Institute INSTANT, Dusseldorf - Germany, European Reference Center WHO - Robert Koch Institute, Berlin, Germany and WHO Regional Measles Reference Laboratory -VIDRL, Melbourne, Australia.
Offered tests in laboratory
Price list of paid services provided by NCIPD, MS№ 255/17.10.2012,
|Code||Laboratory tests||Price in lev|
|315||Qualitative detection of Measles IgM antibodies by ELISA||17,00|
|316||Qualitative detection of Mumps IgM antibodies by ELISA||17,00|
|317||Qualitative detection of Rubella IgM antibodies by ELISA||17,00|
|343||Qualitative detection of Measles IgG antibodies by ELISA||17,00|
|344||Qualitative detection of Mumps IgG antibodies by ELISA||17,00|
|345||Qualitative detection of Rubella IgG antibodies by ELISA||17,00|
|362||Diagnosis of parvovirus B19 infection by ELISA - IgM marker||17,00|
|363||Diagnosis of parvovirus B19 infection by ELISA - IgG marker||17,00|
|237||Proving of the nucleic acid of microorganisms with polymerase chain reaction||41,00|
Requirement about accompanying letter and clinical specimens
Accompanying letter should contain:
• Patient data: name, age, date of illness / contact, MMR vaccination history [date(s) if known]
• Clinical signs and symptoms
• The laboratory marker which must be detected
- Type of virus specimen and date collected
- Date serum sample collected
- Contact name (hospital and medical doctor) with telephone number and/or email address
Instructions for taking specimen for serological testing of markers for acute and / or past infection with measles, mumps, rubella and parvovirus B19 - blood, serum / plasma and / or liquor:
- Blood sample is taken in labeled a closed system Vacutainer® gel for separation of serum or EDTA for separation of plasma; centrifuged serum; and transportation through cold chain (2-8 ° C);
Instructions for taking of clinical material for molecular-biological detection of outbreaks of measles, mumps, rubella, and proof of congenital rubella infection:
• Morning or first urine which must be sterile taken - 10-50 ml collected no later than the fourth day after rash onset, transportation through cold chain (2-8 ° C);
• Oral or buccal swab samples by wiping of the mucous membranes of the nasopharynx with Viral CULTURETTE® or sterile swab in a 2 ml sterile viral transport medium (VTM), storage at 4°C and transporting to 48 hours with coolers.
PhD dissertations and important publications:
- . „Sero-epidemiological studies in pregnant women in contact with rubella and some experimental data on the reproduction of rubella virus”, Sofia,
- . „Morpho-functional studies on spermatogenesis of infertile men with azoospermia”, Sofia,
- А. Toshev. „Distribution of Erythroviruses in Bulgaria, serological, virological and molecular genetic studies”, Sofia, 2015.
ü Ivanova St., Mihneva Z, Toshev A, Kovaleva V, Andonova L, Muller C, Hubschen J. Insights into epidemiology of human parvovirus B19 and detection of an unusual genotype 2 variant, Bulgaria, 2004 to 2013. Euro Surveill. 2016, 21(4):pii=30116.
ü Ivanova St., Z. Mihneva, L. Marinova. Molecular biological studies of patients positive for measles virus during the period of measles elimination process in Bulgaria. Comp. Ren.de l’Acad. Bulg. Des. Sci., 67, 2014, 1, 131-138
ü Toshev A., St. Ivanova, L. Andonova, V. Kovaleva, Z. Mihneva. Detection of Human Parvovirus B19 (HPVB19) in serum samples from fever-rash ill individuals during the rubella outbreak (2005) in Bulgaria. Biotechnology & Biotechnological Equipment, Volume 28, Issue 6, 2014, pages 1103-1107.
ü Stefka Kr. Ivanova, Petia D. Genova-Kalou, Silvia Em. Voleva, Svetla G. Angelova, Borislav M. Marinov, Viktor Em. Manolov, Stoian Shishkov. Infectious Agents and Miscarriage in Bulgaria. American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2016) Volume 25, No 1, pp 1-10.
ü Ivanova St., A. Toshev, Z. Mihneva. Detection of erythrovirus B19 (EVB19) in patients with hematologic diseases (pilot study). Problems of Infectious and Parasitic Diseases, vol 42, Number 2/2014, 22-24.